InflaRx N.V.

NasdaqGS:IFRX Stock Report

Market Cap: US$350.6m

InflaRx Management

Management criteria checks 2/4

InflaRx's CEO is Niels Riedemann, appointed in Jan 2007, has a tenure of 19.33 years. directly owns 1.48% of the company’s shares, worth $5.18M. The average tenure of the management team and the board of directors is 3.8 years and 7 years respectively.

Key information

Niels Riedemann

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure19.3yrs
CEO ownership1.5%
Management average tenure3.8yrs
Board average tenure7yrs

Recent management updates

Recent updates

Analysis Article • Feb 06

Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 20

InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)

Summary InflaRx faces worsening prospects as Gohibic remains niche, unprofitable, and unlikely to drive meaningful revenue growth. Attempts to expand vilobelimab into new indications failed, prompting a strategic pivot to the early-stage asset INF904. Early INF904 data in HS and CSU are underwhelming, with class safety concerns and past failures weighing on IFRX's outlook. With dwindling cash reserves and a high burn rate, IFRX is rated a clear 'Sell' due to excessive risks and uncertain turnaround. Read the full article on Seeking Alpha
Analysis Article • Jul 10

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 25

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 23

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 17

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 28

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 30

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

German clinical-stage biopharma InflaRx (NASDAQ:IFRX) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track designation from the U.S. drug regulator for vilobelimab. IFRX stock +5.6% to $2.63 in early trading. The submission for the emergency use nod and the fast track clearance was based on the results of phase 3 studies conducted in invasively mechanically ventilated, critically ill COVID patients, IFRX said in a statement. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The submission from InflaRx (IFRX) comes at a time when COVID cases in the U.S. are expected to rise in the fall and winter season.
Seeking Alpha • Aug 05

InflaRx reports Q2 results

InflaRx press release (NASDAQ:IFRX): Q2 GAAP EPS of €0.01. On June 30, 2022, the Company’s total funds available were approximately €91.8 million, composed of cash and cash equivalents of €15.4 million and marketable securities of €76.4 million. These funds are expected to finance operations until year-end 2024.
Seeking Alpha • Jul 26

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

InflaRx (NASDAQ:IFRX) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company said it had encouraging interactions with the U.S. Food and Drug Administration (FDA) at a recent Type B meeting which was held to discuss a potential EUA filing and the development of monoclonal antibody vilobelimab for critically ill invasively mechanically ventilated patients with COVID-19. InflaRx noted that it discussed in detail a completed phase 3 part of the PANAMO study in invasively mechanically ventilated, critically ill patients with COVID-19. In March, the company reported data from the phase 3 trial in which vilobelimab did not show statistical significance in reducing risk of death in mechanically ventilated patients with COVID-19. "Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients," said InflaRx Founder and CEO Riedemann.
Analysis Article • Jul 16

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 06

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release. Vilobelimab has already received orphan drug status for PG in the U.S. and EU. IFRX +14.08% to $1.62 premarket July 6
Seeking Alpha • Jun 29

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

German biotech InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday that the FDA agreed to a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab  InflaRx (IFRX) has engaged the agency to discuss the future regulatory path for vilobelimab in COVID-19 after its multi-national PANAMO study for patients with the severe form of the disease generated favorable Phase 3 results early this year. The FDA has scheduled a Type B meeting for early Q3 to provide guidance on a potential emergency use authorization submission. Meanwhile, the discussions with the European Medicines Agency (EMA) are currently underway, targeting a regulatory submission for the same indication. Updating on the development of vilobelimab for the rare skin disorder pyoderma gangrenosum, InflaRx (IFRX) said that the company is now finalizing the design for a Phase III trial. That was after an end-of-phase II meeting, in which the FDA supported a randomized, controlled late-stage study and offered to review the study protocol. Read more on the topline data from the PANAMO study.
Analysis Article • Apr 01

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 29

Our First Look At InflaRx

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below.

CEO

Niels Riedemann (52 yo)

19.3yrs
Tenure

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. He founded InflaRx N.V. in 2007 as InflaRx GmbH. He spent several years in bas...

Leadership Team

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder19.3yrsno data1.48%
$ 5.2m
Renfeng Guo
Co-Founder19.3yrsno data2.44%
$ 8.5m
Thomas Taapken
Chief Financial Officer5.6yrsno data0.0048%
$ 17.0k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance3.1yrsno data0%
$ 0
Camilla Chong
Chief Medical Officer2.8yrsno data0%
$ 0
Jan Medina
Head of Investor Relations & VP2.3yrsno datano data
Christian Schmid
VP and Head of Legal Affairs & General Counselno datano datano data
Maria Habel
VP, Head of Preclinical R&D and QC13.3yrsno datano data
Kofi Boaten
VP and Head of Supply Quality & Clinical Trial Suppliesno datano datano data
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno datano datano data
Daniel Vetter
Senior Director & Head of IT3.8yrsno datano data
Igor Orshanskiy
Senior Director & Head of Business Development2.5yrsno datano data
3.8yrs
Average Tenure
57yo
Average Age

Experienced Management: IFRX's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founderno datano data1.48%
$ 5.2m
Renfeng Guo
Co-Founderno datano data2.44%
$ 8.5m
Nicolas Fulpius
Independent Chairman of the Board19.3yrsno data0.68%
$ 2.4m
K. Reinhart
Member of Scientific Advisory Boardno datano datano data
P. Ward
Member of Scientific Advisory Boardno datano datano data
Richard Brudnick
Independent Non-Executive Director7yrsno data0.069%
$ 242.4k
Hege Hellstrom
Non-Executive Director3.1yrsno data0%
$ 0
Mark Kubler
Independent Non-Executive Director11.3yrsno data1.33%
$ 4.7m
Anthony Gibney
Independent Non-Executive Director5yrsno data0.014%
$ 48.5k
7.0yrs
Average Tenure
54yo
Average Age

Experienced Board: IFRX's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 08:50
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InflaRx N.V. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.